Merida Biosciences
Biotechnology company advancing a precision immunology approach for antibody-driven diseases that selectively and durably eliminate pathogenic B cells while preserving protective immunity.
Website
https://www.meridabio.comLocation
Cambridge, Massachusetts, USA
Founded
2021
Categories
biotech, precision-immunology, autoimmune-disease, antibody-therapeutics, b-cell
Notes
Merida Biosciences is a biotechnology company pioneering precision immunology approaches for the treatment of antibody-driven autoimmune diseases. The company's technology platform is designed to selectively eliminate pathogenic B cells—the source of disease-causing autoantibodies—while preserving the protective immune cells that fight infections.
This precision approach aims to provide durable remissions for patients with autoimmune diseases without the immunosuppression associated with broad B cell depletion therapies.
Team
- Information on leadership team pending further research
Additional Research Findings
- Founded around 2021
- Headquartered in Cambridge, Massachusetts
- Precision immunology approach
- Focus on antibody-driven autoimmune diseases
- Selective B cell targeting technology
- Aims to preserve protective immunity
- Part of growing precision medicine in autoimmunity